Company intelligence / Profile preview

OrthoLogic Corp.

Ownership: Private
Employees: ~50
Development stage: Other

Overview

OrthoLogic developed both marketed medical devices for bone growth stimulation and a pipeline of synthetic therapeutic peptides targeting tissue repair and fibrosis. Its lead peptide candidate Chrysalin® showed positive results in Phase I/II studies for fracture healing and was cleared for Phase III trials by the FDA around the mid-late 2000s. The company also advanced AZX100 into preclinical development for fibrotic diseases but did not reach commercialization before rebranding as Capstone Therapeutics in late September, 2008.[4][5][9]

Therapeutic areas: OtherPulmonologyEndocrinologyCardiovascular
Modalities: Synthetic peptidesMedical devices (bone growth stimulators)
Industry: Biotech

Drug pipeline

1 asset

azx-100

Partnerships

Quintiles Transnational Corp. alliance to develop Chrysalin® [4]; no other major pharma partnerships noted.

Beyond the preview

Go deeper on OrthoLogic Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OrthoLogic Corp..